Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coya Therapeutics, Inc. (COYA : NSDQ)

• Company Description    Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya Therapeutics Inc. is based in HOUSTON. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $3.94 Daily Weekly Monthly 20 Day Moving Average: 123,580 shares Shares Outstanding: 23.46 (millions) Market Capitalization: $92.42 (millions) Beta: 0.58 52 Week High: $6.81 52 Week Low: $3.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -23.94% -23.14% 12 Week -3.43% -5.79% Year To Date -32.07% -36.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5850 San Felipe St Suite 500 - HOUSTON,TX 77057 USA ph: 800-587-8170 fax: - ir@coyatherapeutics.com http://www.coyatherapeutics.com

• General Corporate Information    Officers Arun Swaminathan - Chief Executive Officer and Director Howard Berman - Executive Chairman David Snyder - Chief Financial Officer Ann Lee - Director Anabella Villalobos - Director Peer Information Coya Therapeutics, Inc. (CORR.) Coya Therapeutics, Inc. (RSPI) Coya Therapeutics, Inc. (CGXP) Coya Therapeutics, Inc. (BGEN) Coya Therapeutics, Inc. (GTBP) Coya Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22407B108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 23.46 Most Recent Split Date: (:1) Beta: 0.58 Market Capitalization: $92.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.14 Price/Cash Flow: - Price / Sales: 11.53 EPS Growth vs. Year Ago Period: 22.22% vs. Previous Quarter: 12.50% Sales Growth vs. Year Ago Period: 48.78% vs. Previous Quarter: -2.79% ROE 09/30/26 - - 06/30/26 - -52.05 03/31/26 - -55.86 ROA 09/30/26 - - 06/30/26 - -46.34 03/31/26 - -48.86 Current Ratio 09/30/26 - - 06/30/26 - 13.40 03/31/26 - 15.02 Quick Ratio 09/30/26 - - 06/30/26 - 13.40 03/31/26 - 15.02 Operating Margin 09/30/26 - - 06/30/26 - -263.79 03/31/26 - -259.60 Net Margin 09/30/26 - - 06/30/26 - -270.22 03/31/26 - -266.10 Pre-Tax Margin 09/30/26 - - 06/30/26 - -270.18 03/31/26 - -266.07 Book Value 09/30/26 - - 06/30/26 - 1.84 03/31/26 - 2.09 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©